University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Byron C. Hann, MD, PhD

Byron C. Hann, MD, PhD

Associate Researcher, Manager of Preclinical Therapeutics Core, UCSF Helen Diller Family Comprehensive Cancer Center

Education

Reed College, Portland, Oregon, B.A., 1984, Physics
University of California, San Francisco, CA, Medical Scientist’s Training Program
University of California, San Francisco, CA, Ph.D., 1992, Biochemistry and Biophysics
University of California, San Francisco, CA, M.D., 1994, School of Medicine


Professional Experience

  • 1983-1984
    Undergraduate: Senior Thesis, Physics, Chemistry Department, Reed College, "UV Spectroscopy of Wursters Blue; A Test of Huckel MO Theory". Advisors; Drs. Rich Bettega, Dennis Hoffman
  • 1984
    Research Assistant, Laboratory of Dr. Steve Arch, Reed College Dept. of Biology. Analysis of neuropeptides released by bag cells of Aplysia californica.
  • 1984-1985
    Post Graduate Research Physiologist, Laboratory of Dr. Louis Reichardt, UCSF School of Medicine, Dept of Physiology, Division of Neuroscience. Purification, characterization and cloning of a laminin binding protein.
  • 1988-1992
    Ph.D. candidate, Laboratory of Dr. Peter Walter, UCSF School of Medicine, Dept. of Biochemistry and Biophysics. Identification and analysis of the signal recognition particle in Saccharomyces cerevisiae.
  • 1994-1997
    Post-doctoral fellow, Laboratory of Prof. David Lane, CRC Labs, Department of Biochemistry, University of Dundee, Scotland. Phospho-regulation of p53: Identification of novel sites of p53 phosphorylation, generation of phospho-peptide antibodies, characterization of ATM, ATR phosphorylation of p53 in collaboration with S. Jackson Lab (Cambridge, England).
  • 1997-1999
    Associate Scientist, Onyx Pharmaceuticals, Richmond, CA, Viral therapy and Cell Cycle groups. Analysis of the mechanism of action and selectivity of an onco-lytic, E1B 55-K deficient adenovirus (ONYX-015).
  • 1999-2004
    Specialist, Laboratory of Dr. Allan Balmain, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco CA. The role of p53 in regulating viral and cellular processes in primary and tumor human cells infected with E1B 55-K deficient adenoviruses. p53 dependent abrogation of 55-K deficient virus replication.
  • 2004-present
    Associate Researcher, Director of UCSF Preclinical Core. Working closely with UCSF Breast and Prostate SPORE programs, RTK U54 program, and Pancreas Cancer Research Group to develop new animal models for preclinical studies and to oversee preclinical trials testing novel experimental therapeutics, diagnostics and imaging strategies.

Honors & Awards

  • 1984
  • Phi Beta Kappa
  • President's Award for Excellence in Scholarship, Reed College, Portland, OR

Selected Publications

  1. Harel ET, Drake PM, Barfield RM, Lui I, Farr-Jones S, Van't Veer L, Gartner ZJ, Green EM, Lourenço AL, Cheng Y, Hann BC, Rabuka D, Craik CS. Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer. Antibodies (Basel). 2019 Nov 05; 8(4).
    View on PubMed
  2. Rajaram S, Roth MA, Malato J, VandenBerg S, Hann B, Atreya CE, Altschuler SJ, Wu LF. A multi-modal data resource for investigating topographic heterogeneity in patient-derived xenograft tumors. Sci Data. 2019 10 31; 6(1):253.
    View on PubMed
  3. Harel E, Shoji J, Abraham V, Miller L, Laszik ZG, King A, Dobi D, Szabo G, Hann B, Sarwal MM, Craik CS, Vincenti F. Further Evidence that the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes. Transplantation. 2019 Aug 19.
    View on PubMed
  4. Fontaine SD, Hann B, Reid R, Ashley GW, Santi DV. Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft. Cancer Chemother Pharmacol. 2019 Oct; 84(4):729-738.
    View on PubMed
  5. Scott GK, Yau C, Becker BC, Khateeb S, Mahoney S, Jensen MB, Hann B, Cowen BJ, Pegan SD, Benz CC. Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition. Mol Cancer Ther. 2019 Aug; 18(8):1374-1385.
    View on PubMed
  6. Lou K, Steri V, Ge AY, Hwang YC, Yogodzinski CH, Shkedi AR, Choi ALM, Mitchell DC, Swaney DL, Hann B, Gordan JD, Shokat KM, Gilbert LA. KRASG12C inhibition produces a driver-limited state revealing collateral dependencies. Sci Signal. 2019 May 28; 12(583).
    View on PubMed
  7. Harel E, Shoji J, Abraham V, Miller L, Laszik Z, Thurison T, King A, Olshen A, Leung J, Szabo G, Hann B, Høyer-Hansen G, Craik CS, Vincenti F. Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation. Clin Transplant. 2019 Mar; 33(3):e13487.
    View on PubMed
  8. Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. Mol Cancer Ther. 2018 12; 17(12):2702-2709.
    View on PubMed
  9. Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018 09 06; 3(17).
    View on PubMed
  10. Shao H, Li X, Moses MA, Gilbert LA, Kalyanaraman C, Young ZT, Chernova M, Journey SN, Weissman JS, Hann B, Jacobson MP, Neckers L, Gestwicki JE. Exploration of Benzothiazole Rhodacyanines as Allosteric Inhibitors of Protein-Protein Interactions with Heat Shock Protein 70 (Hsp70). J Med Chem. 2018 Jul 26; 61(14):6163-6177.
    View on PubMed
  11. Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet C, Tameire F, Evans MJ, Evans CP, Yang JC, Hann B, Koumenis C, Walter P, Carroll PR, Ruggero D. Development of a stress response therapy targeting aggressive prostate cancer. Sci Transl Med. 2018 05 02; 10(439).
    View on PubMed
  12. Lam C, Ferguson ID, Mariano MC, Lin YT, Murnane M, Liu H, Smith GA, Wong SW, Taunton J, Liu JO, Mitsiades CS, Hann BC, Aftab BT, Wiita AP. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica. 2018 07; 103(7):1218-1228.
    View on PubMed
  13. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107.
    View on PubMed
  14. Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ. Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res. 2017 09; 15(9):1221-1229.
    View on PubMed
  15. Lu X, Peled N, Greer J, Wu W, Choi P, Berger AH, Wong S, Jen KY, Seo Y, Hann B, Brooks A, Meyerson M, Collisson EA. MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma. Cancer Res. 2017 08 15; 77(16):4498-4505.
    View on PubMed
  16. Spangler B, Fontaine SD, Shi Y, Sambucetti L, Mattis AN, Hann B, Wells JA, Renslo AR. A Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer Models. J Med Chem. 2016 12 22; 59(24):11161-11170.
    View on PubMed
  17. Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016 12 01; 126(12):4640-4653.
    View on PubMed
  18. Scott GK, Chu D, Kaur R, Malato J, Rothschild DE, Frazier K, Eppenberger-Castori S, Hann B, Park BH, Benz CC. ERpS294 is a biomarker of ligand or mutational ERa activation and a breast cancer target for CDK2 inhibition. Oncotarget. 2017 Oct 13; 8(48):83432-83445.
    View on PubMed
  19. Rozanov D, Cheltsov A, Sergienko E, Vasile S, Golubkov V, Aleshin AE, Levin T, Traer E, Hann B, Freimuth J, Alexeev N, Alekseyev MA, Budko SP, Bächinger HP, Spellman P. TRAIL-Based High Throughput Screening Reveals a Link between TRAIL-Mediated Apoptosis and Glutathione Reductase, a Key Component of Oxidative Stress Response. PLoS One. 2015; 10(6):e0129566.
    View on PubMed
  20. Li X, Colvin T, Rauch JN, Acosta-Alvear D, Kampmann M, Dunyak B, Hann B, Aftab BT, Murnane M, Cho M, Walter P, Weissman JS, Sherman MY, Gestwicki JE. Validation of the Hsp70-Bag3 protein-protein interaction as a potential therapeutic target in cancer. Mol Cancer Ther. 2015 Mar; 14(3):642-8.
    View on PubMed

Go to UCSF Profiles, powered by CTSI